Beckley Psytech

Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth

Beckley Psytech Doses First Patients With Psilocin In Trial For Treatment Of Major Depression Disorder

Imperial College Scientists Dose First Patient With 5-MeO-DMT To Examine One Of The Most Potent Psychedelics' Effects On The Brain

Beckley Psytech Doses First Patients With Psilocin In Trial For Treatment Of Major Depression Disorder

Imperial College Scientists Dose First Patient With 5-MeO-DMT To Examine One Of The Most Potent Psychedelics' Effects On The Brain

First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression

UK-Based Approach To Alcohol Addiction: 5-MeO-DMT Candidate Moves To Phase 2 Clinical Stage

First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression

UK-Based Approach To Alcohol Addiction: 5-MeO-DMT Candidate Moves To Phase 2 Clinical Stage

Phase 2 Trial For This Psychedelic, Potential Treatment For Severe Depression

Beyond Magic Mushrooms: Positive Clinical Trial For Treatment-Resistant Depression & Alcoholism

Beckley Psytech Recent News

Psychedelics M&A: Beckley Psytech Acquires Eleusis Therapeutics, Strengthening Drug Pipeline And R&D Team

Private psychedelics medicine company Beckley Psytech Ltd. has acquired 100% of clinical-stage life sciences company Eleusis Therapeutics Ltd., entitling the former to full developmental and commercial rights of the latter’s assets.

Palo Santo Closes $50M Psychedelic Therapeutics Investment Fund

Palo Santo, a venture capital fund focused on backing and building emerging psychedelic therapeutics companies, recently announced the closing of its $50 million fund.

Psyched: UK Streamlines MDMA Therapy, FDA OKs MindMed's First LSD Trial In 40 years, Atai Launches Subsidiary

The Week In Psychedelics

Beckley Psytech Begins Training Therapists For Phase 2 Trial With Toad Venom, 5-MeO-DMT

Beckley Psytech, a private company in the psychedelics space, announced that it has begun training psychotherapists for a Phase 2 clinical trial with 5-MeO-DMT, a strong and fast-acting psychedeli

Psyched: Beckley Psytech Raises $80M, Diamond Therapeutics To Study Psilocybin Microdosing, Mydecine and Johns Hopkins Partner Up

Beckley Psytech Closes $80 Million Series B

Beckley Psytech Reaches $100M Financing To Study 5-MeO-DMT, Psilocybin And Other Psychedelics

Beckley Psytech, an Oxford-based psychedelics research company, announced the closing of a £58 million ($80 million) Series B raise, which will be used to further finance the company’s psilocybin and

Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies

This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Psilocybin Alpha. In just a couple of years, psychedelics took the world of investing by storm.

Psychedelic Compound 5-MeO-DMT Could Make Therapy Short And Effective: Beckley Psytech Is 'All In'

5-MeO-DMT is a potent and fast-acting psychedelic, which is naturally produced by the Sonoran Desert toad as well as some species of plants. Its short duration –from 20 minutes to one hour– is giving hope to researchers and executives in the psychedelics space who are seeking an alternative to the otherwise lengthy treatment sessions of psilocybin and MDMA.

Psyched: The First Psychedelics ETF, Beckley Raises $19M, 3 Companies Go Public

The Psychedelics Sector Might Soon Get Its First ETF Financial services company Horizons ETFs Management filed documents with the Ontario Securities Commission for a psychedelics ETF, which is expected to go live on Jan. 15.

'Psyched': Atai Buys Kures, Beckley Psytech Raises $3.7M, Mydecine Acquires NeuroPharma

PSYCHED is now weekly! As the psychedelics industry grows, so does the need for news. For this reason, our column covering the most important developments in medicinal psychedelics is now a weekly feature.

;